Conclusions and RelevanceIn adults with mild to moderate hypertension, treatment with zilebesiran across a range of doses at 3-month or 6-month intervals significantly reduced 24-hour mean ambulatory SBP at month 3. Trial RegistrationClinicalTrials.gov Identifier: NCT04936035. ---分割线---...
Trial Registration ClinicalTrials.gov Identifier:NCT04936035doi:10.1001/jama.2024.0728George L.Bakris, MDManishSaxena, MBBSAnilGupta, MDFadiChalhoub, MDJongtaeLee, MDDanielStiglitz, MScNuneMakarova, MDNitenderGoyal, MDWeinongGuo, MDDionZappe, PhD...